Brand Protection for Pharmaceutical Companies
WHO data shows 1 in 10 medical products in developing markets is substandard or falsified. Your patients trust your label. Make sure what's inside lives up to it.
Counterfeiting in Pharma Is Not a Niche Problem
Most pharma brands discover they have a counterfeiting problem after something goes wrong. A patient complaint. A regulator inquiry. A fake product trending on social media. By then the damage is already done.
Six Ways Your Products Get Compromised in the Field
A patient takes your product. The packaging is yours. The lot number is real. But the API inside is diluted or substituted. You find out when an adverse event report comes in. At that point it is a crisis, not a supply chain issue.
Product meant for Germany ends up in Nigeria. Your authorised distributor sold it on. The recipient market has no DSCSA or FMD verification in place. Your compliance team gets a call from a regulator asking why your serialised pack verified in the wrong country.
Fake versions of your blockbuster drug are listed on five pharmacy platforms. Patients order them. Some get no effect. Some get worse. And your brand protection team only finds out when a consumer forum post goes viral.
Used blister packs, vials, and cartons are collected from pharmacies and refilled with substandard product. The packaging is genuine and passes visual checks at every step. Only a digital scan reveals that it has already been dispensed.
A former contract manufacturer is producing your formulation and selling it under your label. They know your batch numbers, your packaging specs, and your distribution network. Without serialised unique IDs at unit level, you cannot distinguish theirs from yours.
Near-expired product recalled from authorised channels comes back with altered lot numbers and expiry dates. It clears warehouse intake checks because the label looks valid. Batch-level traceability on blockchain is the only way to catch this consistently.
Four Mandates Your Team Is Probably Already Tracking
If you sell in the US, EU, or India, at least two of these apply to you right now. Acviss maps to each one so you do not have to build separate systems for separate markets.
Item-level serialisation for every prescription drug sold in the US. Each handoff between manufacturer, wholesaler and dispenser requires Transaction Information, Transaction History, and Transaction Statements in the EPCIS format. Full interoperability was mandated from November 2023.
2D DataMatrix with unique identifier, batch number, and expiry date is mandatory on all EU prescription packs. Products must verify against the European Medicines Verification System repository at point of dispense. Failure to verify means the product cannot be dispensed legally.
Revised Schedule M (effective January 2025) requires GMP-certified manufacturers to implement serialisation, barcoding, and batch traceability. CDSCO is phasing in serialisation requirements for drug exports. Form 41 audit trails are required for inspection readiness.
WHO Good Manufacturing Practice guidelines and the Pharmaceutical Inspection Co-operation Scheme both require documented traceability from raw material to finished product. PIC/S membership covers 53 countries. If you export to any of them, this applies to you.
Certify. Track. Monitor.
Three products that can work on their own or together as one platform. Start with the part that matters most to you right now and add the rest when you are ready.
Every pack gets a unique digital identity. Patients scan and know in seconds whether what they bought is real. Your QA team gets the data they need without chasing distributors for spreadsheets.
- Unit-level 2D DataMatrix and QR code generation
- Tamper-evident holographic labels with digital twin
- Consumer scan-to-verify with no app or login needed
- Batch reporting dashboard for QA and compliance teams
- EMVS-compatible export for EU FMD repository upload
- DSCSA serialisation data elements built in
Know exactly where every batch is at every moment. When a regulator asks for your chain of custody, you pull it up in seconds. When a distributor diverts product, you get an alert before it reaches the patient.
- Blockchain chain-of-custody from manufacturer to dispenser
- GPS-tagged scan events at every supply chain node
- Cold chain temperature and handling event logging
- Automatic alert when a product scans in the wrong geography
- CDSCO-ready audit trail with Form 41 data export
- WHO-GMP and PIC/S inspection documentation support
Your brand protection team cannot manually search every pharmacy platform every day. Truviss does it for them. When a fake listing appears, they get an alert with the evidence already packaged for takedown.
- AI-powered detection of counterfeit listings across platforms
- Alerts for rogue pharmacy sites and brand impersonation
- Evidence packaged and ready for platform takedown submission
- Grey market diversion monitoring by country and channel
- Social media monitoring for unlicensed sellers
- Weekly threat intelligence reports for your legal and IP teams
See How Acviss Supports Pharma Online Brand Protection
Get a tailored online brand protection plan for your Pharma products and channels.
- ✅ Risk Audit: We map your Pharma product, channel, and customer journey.
- ✅ Live Demo: See Acviss online brand protection workflows on your use case.
- ✅ Tailored Rollout: Get a practical deployment plan for your products and existing systems.
Trusted by Leading Brands
Protect Products.Build Trust.
Things Pharma Teams Ask Us
Your Patients Deserve to Know What They Are Taking Is Real.
80+ brands across 11+ countries use Acviss to protect their products and stay ahead of regulators. Book a call and we will show you where your gaps are and what it takes to close them.
